Combining elacestrant with targeted agents produced “clinically meaningful” outcomes for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer who have received at least ...

AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved by the US FDA to treat adult ...

US FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab for 1st-line treatment of patients with HER2-positive metastatic breast cancer: Cambridge, UK Wednesday, ...

FDA approves AstraZeneca and Daiichi's Enhertu combo for first-line HER2-positive breast cancer, while the EU clears Saphnelo ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

AstraZeneca PLC AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug conjugate (ADC), Enhertu, for first-line use in breast cancer.

Analysts at Jefferies called the approval "highly significant," estimating it could add $2 billion to $3 billion to peak ...

FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the USA ...

Enhertu is already approved as a second-line or later treatment for HER2-positive breast cancer, along with other indications ...

Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research ...

Drugmaker AstraZeneca chalked up two regulatory wins on Tuesday, with approvals in both the US and Europe for key treatments ...